

Stephen C Rubin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8946874/publications.pdf>

Version: 2024-02-01

236
papers

16,519
citations

14655

66
h-index

16650

123
g-index

238
all docs

238
docs citations

238
times ranked

13790
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. <i>New England Journal of Medicine</i> , 2003, 348, 203-213.	27.0	2,930
2	Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.. <i>Journal of Clinical Oncology</i> , 1991, 9, 389-393.	1.6	781
3	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 533-543.	2.5	732
4	Bevacizumab and paclitaxel+carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 779-791.	10.7	460
5	Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of <i>BRCA1</i> . <i>New England Journal of Medicine</i> , 1996, 335, 1413-1416.	27.0	408
6	Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma. <i>New England Journal of Medicine</i> , 2004, 351, 2489-2497.	27.0	366
7	Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 83-89.	1.6	331
8	Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 738-748.	27.0	303
9	Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study.. <i>Journal of Clinical Oncology</i> , 1992, 10, 1485-1491.	1.6	295
10	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation + An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 137, 386-391.	1.4	224
11	Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2006, 101, 436-440.	1.4	205
12	Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2011, 123, 19-26.	1.4	193
13	Vascular leukocytes contribute to tumor vascularization. <i>Blood</i> , 2005, 105, 679-681.	1.4	183
14	Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.. <i>Journal of Clinical Oncology</i> , 1991, 9, 1801-1805.	1.6	178
15	Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1380-1390.	1.6	178
16	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. <i>Clinical Cancer Research</i> , 2018, 24, 777-783.	7.0	171
17	BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: Relationship to family history and implications for genetic testing. <i>American Journal of Obstetrics and Gynecology</i> , 1998, 178, 670-677.	1.3	167
18	Prevalence and Predictors of Psychological Distress Among Women With Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 919-926.	1.6	161

#	ARTICLE	IF	CITATIONS
19	Treatment of endometrial stromal tumors. <i>Gynecologic Oncology</i> , 1990, 36, 60-65.	1.4	160
20	Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. <i>Cancer</i> , 1994, 73, 1882-1888.	4.1	156
21	Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 1992, 45, 284-289.	1.4	151
22	Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With <i>BRCA1/2</i> Mutations: A Decision Analysis. <i>Journal of Clinical Oncology</i> , 2004, 22, 1045-1054.	1.6	150
23	Clinical Characteristics of Clear Cell Carcinoma of the Ovary. <i>Gynecologic Oncology</i> , 1998, 70, 255-258.	1.4	146
24	Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2620-2624.	1.6	133
25	Cytoreductive Surgery in Ovarian Carcinoma Patients with a Documented Previously Complete Surgical Response. <i>Gynecologic Oncology</i> , 1995, 57, 61-65.	1.4	132
26	Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma. <i>American Journal of Pathology</i> , 2002, 161, 2295-2309.	3.8	129
27	Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.. <i>Journal of Clinical Oncology</i> , 1992, 10, 243-248.	1.6	124
28	Molecular Evidence for Multifocal Papillary Serous Carcinoma of the Peritoneum in Patients With Germline <i>BRCA1</i> Mutations. <i>Journal of the National Cancer Institute</i> , 1998, 90, 841-845.	6.3	123
29	Paget's disease of the vulva. <i>Gynecologic Oncology</i> , 1990, 39, 374-377.	1.4	122
30	Resection of pulmonary metastases from uterine sarcomas. <i>Gynecologic Oncology</i> , 1992, 45, 202-205.	1.4	122
31	Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 1989, 34, 365-371.	1.4	121
32	Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. <i>Obstetrics and Gynecology</i> , 1999, 93, 21-24.	2.4	120
33	Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. <i>American Journal of Obstetrics and Gynecology</i> , 1993, 168, 162-169.	1.3	119
34	Intraepithelial T cells and tumor proliferation. <i>Cancer</i> , 2009, 115, 2891-2902.	4.1	118
35	Palliative surgery for intestinal obstruction in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 1989, 34, 16-19.	1.4	114
36	Hereditary Ovarian Cancer: Molecular Genetics and Clinical Implications. <i>Gynecologic Oncology</i> , 1997, 64, 196-206.	1.4	113

#	ARTICLE	IF	CITATIONS
37	Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 1991, 42, 137-141.	1.4	111
38	Management of vulvar melanoma. <i>Gynecologic Oncology</i> , 1992, 45, 254-258.	1.4	111
39	Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 629-641.	4.2	109
40	Phase II Trial of Debulking Surgery and Photodynamic Therapy for Disseminated Intraperitoneal Tumors. <i>Annals of Surgical Oncology</i> , 2001, 8, 65-71.	1.5	104
41	A Phase II Trial of Intraperitoneal Photodynamic Therapy for Patients with Peritoneal Carcinomatosis and Sarcomatosis. <i>Clinical Cancer Research</i> , 2006, 12, 2517-2525.	7.0	102
42	Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. <i>Biochemical and Biophysical Research Communications</i> , 2003, 303, 1169-1178.	2.1	101
43	Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1989, 160, 667-671.	1.3	100
44	High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. <i>British Journal of Haematology</i> , 1993, 83, 433-441.	2.5	95
45	Effect of Surgical Debulking on Survival in Stage IV Ovarian Cancer. <i>Gynecologic Oncology</i> , 1997, 64, 4-8.	1.4	93
46	Ovarian Cancer Patients' Psychological Distress: The Role of Physical Impairment, Perceived Unsupportive Family and Friend Behaviors, Perceived Control, and Self-Esteem.. <i>Health Psychology</i> , 2005, 24, 143-152.	1.6	93
47	Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 1989, 7, 1327-1332.	1.6	86
48	Squamous carcinoma of the vagina: Treatment, complications and long-term follow-up. <i>Gynecologic Oncology</i> , 1985, 20, 346-353.	1.4	85
49	Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4151-4159.	1.6	84
50	Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer.. <i>Journal of Clinical Oncology</i> , 1992, 10, 1479-1484.	1.6	81
51	Recurrence after negative second-look laparotomy for ovarian cancer: Analysis of risk factors. <i>American Journal of Obstetrics and Gynecology</i> , 1988, 159, 1094-1098.	1.3	79
52	Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1210-1217.	1.6	77
53	Estrogen Sulfation Genes, Hormone Replacement Therapy, and Endometrial Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1311-1320.	6.3	76
54	Evidence Supporting the Superiority of Intraperitoneal Cisplatin Compared to Intraperitoneal Carboplatin for Salvage Therapy of Small-Volume Residual Ovarian Cancer. <i>Gynecologic Oncology</i> , 1993, 50, 100-104.	1.4	75

#	ARTICLE	IF	CITATIONS
55	The Accuracy of a Frozen Section Diagnosis of Borderline Ovarian Malignancy. <i>Gynecologic Oncology</i> , 1995, 59, 183-185.	1.4	74
56	Occult Bilateral Involvement in Stage I Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1999, 72, 288-291.	1.4	74
57	Case-Control Study of Postmenopausal Hormone Replacement Therapy and Endometrial Cancer. <i>American Journal of Epidemiology</i> , 2006, 164, 775-786.	3.4	74
58	TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. <i>Clinical Cancer Research</i> , 2003, 9, 1517-27.	7.0	73
59	BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum*1. <i>Obstetrics and Gynecology</i> , 1998, 92, 596-600.	2.4	72
60	Ten-Year Follow-Up of Ovarian Cancer Patients After Second-Look Laparotomy With Negative Findings. <i>Obstetrics and Gynecology</i> , 1999, 93, 21-24.	2.4	72
61	Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.. <i>Journal of Clinical Oncology</i> , 1990, 8, 146-150.	1.6	70
62	Primary lymphomas of the cervix and uterus: The University of Pennsylvania's experience and a review of the literature. <i>Leukemia and Lymphoma</i> , 2006, 47, 1894-1901.	1.3	70
63	Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. <i>Cancer</i> , 1994, 73, 1456-1459.	4.1	69
64	Coping and communication-enhancing intervention versus supportive counseling for women diagnosed with gynecological cancers.. <i>Journal of Consulting and Clinical Psychology</i> , 2007, 75, 615-628.	2.0	69
65	Saphenous vein sparing during inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma. <i>Gynecologic Oncology</i> , 2006, 101, 140-142.	1.4	68
66	Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer.. <i>Journal of Consulting and Clinical Psychology</i> , 1990, 58, 153-157.	2.0	67
67	Replication-Selective Herpes Simplex Virus Type 1 Mutant Therapy of Cervical Cancer Is Enhanced by Low-Dose Radiation. <i>Human Gene Therapy</i> , 2002, 13, 627-639.	2.7	65
68	Epithelial ovarian cancer in the elderly: The memorial sloan-kettering cancer center experience. <i>Cancer</i> , 2010, 71, 634-637.	4.1	64
69	Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. <i>Cancer Gene Therapy</i> , 2000, 7, 275-283.	4.6	63
70	Intraperitoneal chemotherapy: Analysis of complications with an implanted subcutaneous port and catheter system. <i>Gynecologic Oncology</i> , 1991, 41, 101-106.	1.4	62
71	A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 123, 486-491.	1.4	59
72	Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 195-203.	2.5	58

#	ARTICLE	IF	CITATIONS
73	Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. <i>Cancer</i> , 1995, 75, 2700-2705.	4.1	57
74	Resilience, Positive Coping, and Quality of Life Among Women Newly Diagnosed With Gynecological Cancers. <i>Cancer Nursing</i> , 2015, 38, 375-382.	1.5	56
75	A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 1988, 6, 689-695.	1.6	55
76	Racial differences in survival from gynecologic cancer. <i>Obstetrics and Gynecology</i> , 1996, 88, 914-918.	2.4	55
77	Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992, 119, 55-57.	2.5	54
78	Vaginal Cuff Recurrence of Endometrial Cancer Treated by Laparoscopic-Assisted Vaginal Hysterectomy. <i>Gynecologic Oncology</i> , 2003, 88, 62-65.	1.4	54
79	Early Invasive Carcinoma of the Cervix. <i>Gynecologic Oncology</i> , 1993, 51, 26-32.	1.4	53
80	Social cognitive processes associated with fear of recurrence among women newly diagnosed with gynecological cancers. <i>Gynecologic Oncology</i> , 2013, 128, 120-127.	1.4	53
81	Endometrial Carcinoma Associated with Pregnancy: A Report of Three Cases and Review of the Literature. <i>Gynecologic Oncology</i> , 1999, 74, 118-122.	1.4	52
82	A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2009, 115, 215-220.	1.4	50
83	Chemotherapy resistance in ovarian cancer: New molecular perspectives. <i>Obstetrics and Gynecology</i> , 1998, 91, 783-792.	2.4	49
84	Disparities in the management and outcome of cervical cancer in the United States according to health insurance status. <i>Gynecologic Oncology</i> , 2016, 141, 516-523.	1.4	49
85	Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 1991, 9, 204-210.	1.6	47
86	Extended-field radiation therapy in early-stage cervical carcinoma: Survival and complications. <i>Gynecologic Oncology</i> , 1991, 43, 51-54.	1.4	46
87	Intraperitoneal chemotherapy in the management of ovarian cancer. <i>Cancer</i> , 1993, 71, 1565-1570.	4.1	46
88	Primary Peritoneal Carcinoma. <i>Obstetrical and Gynecological Survey</i> , 1999, 54, 323-335.	0.4	45
89	CYTOREDUCTIVE SURGERY FOR OVARIAN CANCER. <i>Surgical Clinics of North America</i> , 2001, 81, 871-883.	1.5	44
90	Impact of Age on Survival of Patients with Ovarian Cancer. <i>Gynecologic Oncology</i> , 1993, 49, 236-239.	1.4	43

#	ARTICLE	IF	CITATIONS
91	Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. <i>Clinical Cancer Research</i> , 2003, 9, 264-72.	7.0	43
92	Para-aortic nodal metastases in early cervical carcinoma: Long-term survival following extended-field radiotherapy. <i>Gynecologic Oncology</i> , 1984, 18, 213-217.	1.4	41
93	Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube. <i>Gynecologic Oncology</i> , 1991, 42, 156-160.	1.4	41
94	Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer. , 1998, 82, 152-158.		41
95	Screening for ovarian cancer in the general population. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2006, 20, 307-320.	2.8	41
96	Clinical predictors of bevacizumab-associated gastrointestinal perforation. <i>Gynecologic Oncology</i> , 2011, 120, 464-469.	1.4	40
97	Rapid Delivery of Multiple High-Dose Chemotherapy Courses With Granulocyte Colony-Stimulating Factor and Peripheral Blood-Derived Hematopoietic Progenitor Cells. <i>Journal of the National Cancer Institute</i> , 1992, 84, 1935-1936.	6.3	36
98	Endometrial Adenocarcinoma with Trophoblastic Differentiation. <i>Gynecologic Oncology</i> , 1998, 69, 74-77.	1.4	35
99	The Clinical Course of Deep Vein Thrombosis in Patients with Gynecologic Cancer. <i>Gynecologic Oncology</i> , 2002, 84, 67-71.	1.4	35
100	Expression of P-glycoprotein in epithelial ovarian cancer: Evaluation as a marker of multidrug resistance. <i>American Journal of Obstetrics and Gynecology</i> , 1990, 163, 69-73.	1.3	33
101	Management of endometrial adenocarcinoma with cervical involvement. <i>Gynecologic Oncology</i> , 1992, 45, 294-298.	1.4	33
102	The Use of Recombinant Human Erythropoietin to Prevent Carboplatin-Induced Anemia. <i>Gynecologic Oncology</i> , 1993, 49, 172-176.	1.4	33
103	Radical hysterectomy for recurrent cervical cancer following radiation therapy. <i>Gynecologic Oncology</i> , 1987, 27, 316-322.	1.4	32
104	Aggressive chemosurgical debulking in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 1990, 38, 358-363.	1.4	32
105	Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: A clinically recalcitrant entity. <i>Gynecologic Oncology</i> , 2011, 120, 108-112.	1.4	32
106	Second-look surgery in ovarian carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 1988, 8, 75-91.	4.4	31
107	Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.. <i>Journal of Clinical Oncology</i> , 1991, 9, 978-982.	1.6	31
108	Allelotype analysis of uterine leiomyoma: Localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q. <i>Molecular Carcinogenesis</i> , 1998, 23, 243-247.	2.7	31

#	ARTICLE	IF	CITATIONS
109	Mediators of a coping and communication-enhancing intervention and a supportive counseling intervention among women diagnosed with gynecological cancers.. Journal of Consulting and Clinical Psychology, 2008, 76, 1034-1045.	2.0	31
110	Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. Journal of Cancer Research and Clinical Oncology, 1991, 117, 89-90.	2.5	30
111	Germline Mutations of theBRCA1andBRCA2Genes in a Breast and Ovarian Cancer Patient. Gynecologic Oncology, 1998, 70, 432-434.	1.4	30
112	Long-Term Trajectories of Psychological Adaptation Among Women Diagnosed With Gynecological Cancers. Psychosomatic Medicine, 2008, 70, 677-687.	2.0	30
113	Holding back sharing concerns, dispositional emotional expressivity, perceived unsupportive responses and distress among women newly diagnosed with gynecological cancers. General Hospital Psychiatry, 2014, 36, 81-87.	2.4	30
114	Biodistribution and Intraoperative Evaluation of Radiolabeled Monoclonal Antibody MX 35 in Patients with Epithelial Ovarian Cancer. Gynecologic Oncology, 1993, 51, 61-66.	1.4	28
115	CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER. Obstetrics and Gynecology, 1998, 91, 783-792.	2.4	28
116	Intestinal surgery in gynecologic oncology. Gynecologic Oncology, 1989, 34, 30-33.	1.4	27
117	Immunohistochemical localization of P-glycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions.. Journal of Histochemistry and Cytochemistry, 1990, 38, 1677-1681.	2.5	27
118	Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. American Journal of Obstetrics and Gynecology, 1996, 175, 1260-1265.	1.3	27
119	BRCA1 Gene Mutations in Women With Papillary Serous Carcinoma of the Peritoneum. Obstetrics and Gynecology, 1998, 92, 596-600.	2.4	26
120	Prolonged Remission of Recurrent, Metastatic Placental Site Trophoblastic Tumor after Chemotherapy. Gynecologic Oncology, 2000, 76, 115-117.	1.4	26
121	Comparison of Antigen Expression on Fresh and Cultured Ascites Cells and on Solid Tumors of Patients with Epithelial Ovarian Cancer. Gynecologic Oncology, 1993, 50, 78-83.	1.4	24
122	Expression of A, B, and H Blood Group Antigens in Epithelial Ovarian Cancer: Relationship to Tumor Grade and Patient Survival. Gynecologic Oncology, 1996, 62, 106-112.	1.4	24
123	The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study. International Journal of Gynecological Cancer, 2016, 26, 141-148.	2.5	24
124	Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2018, 149, 525-530.	1.4	24
125	Long-term access to the peritoneal cavity in ovarian cancer patients. Gynecologic Oncology, 1989, 33, 46-48.	1.4	23
126	Well-differentiated adenocarcinoma of endometrium with simple karyotypic changes: A case report. Cancer Genetics and Cytogenetics, 1987, 25, 21-26.	1.0	22

#	ARTICLE	IF	CITATIONS
127	Surgically Documented Responses to Paclitaxel and Cisplatin in Patients with Primary Peritoneal Carcinoma. <i>Gynecologic Oncology</i> , 1996, 62, 55-58.	1.4	22
128	High-Resolution Positron Emission Tomography of Human Ovarian Cancer in Nude Rats Using ¹²⁴ I-Labeled Monoclonal Antibodies. <i>Gynecologic Oncology</i> , 1993, 48, 61-67.	1.4	21
129	Arterial Occlusion Complicating Treatment of Gynecologic Cancer: A Case Series. <i>Gynecologic Oncology</i> , 1996, 63, 40-46.	1.4	21
130	Intestinal Obstruction in Advanced Ovarian Cancer: What Does the Patient Want?. <i>Gynecologic Oncology</i> , 1999, 75, 311-312.	1.4	21
131	A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2011, 121, 264-268.	1.4	21
132	Tissue-based immune monitoring II. <i>Cancer Biology and Therapy</i> , 2011, 12, 367-377.	3.4	21
133	Celiac Axis and Superior Mesenteric Artery Injury Associated with Left Radical Nephrectomy for Locally Advanced Renal Cell Carcinoma. <i>Journal of Urology</i> , 1991, 146, 1104-1107.	0.4	20
134	Monoclonal antibodies in the management of ovarian cancer: A clinical perspective. <i>Cancer</i> , 1993, 71, 1602-1612.	4.1	20
135	OncoLink: A Cancer Information Resource for Gynecologic Oncologists and the Public on the Internet. <i>Gynecologic Oncology</i> , 1996, 60, 8-15.	1.4	20
136	CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. <i>Clinical Cancer Research</i> , 2017, 23, 3684-3691.	7.0	20
137	Lymph node nomenclature in gynecologic oncology. <i>Gynecologic Oncology</i> , 1986, 23, 222-226.	1.4	19
138	Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1991, 164, 558-563.	1.3	19
139	A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 127, 356-361.	1.4	19
140	The Effect of Renal Function on Serum Levels of CA 125. <i>Gynecologic Oncology</i> , 1995, 58, 375-377.	1.4	18
141	Expression and mutational analysis of P53 in stage IB and IIA cervical cancers. <i>American Journal of Obstetrics and Gynecology</i> , 1996, 175, 1266-1271.	1.3	18
142	RNA interference, A potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer. <i>Cancer Biology and Therapy</i> , 2004, 3, 1283-1289.	3.4	18
143	Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy. <i>Gynecologic Oncology</i> , 1991, 43, 159-163.	1.4	17
144	Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1992, 47, 353-357.	1.4	17

#	ARTICLE	IF	CITATIONS
145	Limited-Field Radiotherapy as Salvage Treatment of Localized Persistent or Recurrent Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1993, 51, 349-354.	1.4	17
146	BRCA-related ovarian carcinoma. <i>Cancer</i> , 2003, 97, 2127-2129.	4.1	17
147	Therapy processes and outcomes of psychological interventions for women diagnosed with gynecological cancers: A test of the generic process model of psychotherapy.. <i>Journal of Consulting and Clinical Psychology</i> , 2010, 78, 236-248.	2.0	17
148	Group-based trajectory modeling of fear of disease recurrence among women recently diagnosed with gynecological cancers. <i>Psycho-Oncology</i> , 2017, 26, 1799-1809.	2.3	17
149	Second primary anal and oropharyngeal cancers in cervical cancer survivors. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 478.e1-478.e6.	1.3	17
150	A longitudinal study of antigen expression in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1989, 34, 389-394.	1.4	16
151	Chemoprevention of Hereditary Ovarian Cancer. <i>New England Journal of Medicine</i> , 1998, 339, 469-471.	27.0	16
152	Women with a Prior Diagnosis of Breast Cancer Are Not at an Increased Risk for Subsequent Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2005, 100, 2759-2764.	0.4	16
153	Second-look laparotomy for epithelial ovarian cancer: A reappraisal. <i>Current Oncology Reports</i> , 2001, 3, 11-18.	4.0	15
154	Tumor-Associated Macrophages as a Source of Functional Dendritic Cells in Ovarian Cancer Patients. <i>Clinical Immunology</i> , 2002, 102, 291-301.	3.2	15
155	Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2011, 123, 182-186.	1.4	15
156	The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1-deficient ovarian tumors and can be exploited to improve treatment response in a mouse model. <i>Gynecologic Oncology</i> , 2014, 133, 584-590.	1.4	15
157	Arterial Occlusions as a Presenting Feature of Acute Promyelocytic Leukemia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 436-437.	1.3	15
158	Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer.. <i>Journal of Clinical Oncology</i> , 1988, 6, 158-162.	1.6	14
159	Chemotherapy-induced neutropenia and fever in patients receiving cisplatin-based chemotherapy for ovarian malignancy. <i>Gynecologic Oncology</i> , 1991, 40, 17-20.	1.4	14
160	Secondary cytoreduction in epithelial ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1995, 18, 1-8.	4.4	14
161	Diethyldithiocarbamate chemoprotection of carboplatin-induced hematological toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 1993, 119, 360-362.	2.5	13
162	Isoflurane versus fentanyl: hemodynamic effects in cancer patients treated with anthracyclines. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1993, 7, 307-311.	1.3	13

#	ARTICLE	IF	CITATIONS
163	Surgical management of ovarian cancer. , 1999, 17, 173-180.		13
164	Therapist and patient perceptions of alliance and progress in psychological therapy for women diagnosed with gynecological cancers.. Journal of Consulting and Clinical Psychology, 2012, 80, 800-810.	2.0	13
165	The role of adjuvant radiation in lymph node positive endometrial adenocarcinoma. Gynecologic Oncology, 2016, 141, 434-439.	1.4	13
166	Postmenopausal Bleeding: Etiology, Evaluation, and Management. Medical Clinics of North America, 1987, 71, 59-69.	2.5	12
167	Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy. Journal of Cancer Research and Clinical Oncology, 1992, 118, 163-165.	2.5	12
168	Prophylactic oophorectomy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 597-609.	2.8	12
169	A preoperative risk score to predict red blood cell transfusion in patients undergoing hysterectomy for ovarian cancer. American Journal of Obstetrics and Gynecology, 2018, 219, 598.e1-598.e10.	1.3	12
170	Surgery for Ovarian Cancer. Hematology/Oncology Clinics of North America, 1992, 6, 851-865.	2.2	11
171	Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. International Journal of Gynecological Cancer, 2008, 18, 773-778.	2.5	11
172	Second primary uterine malignancies after radiation therapy for cervical cancer. Archives of Gynecology and Obstetrics, 2019, 300, 389-394.	1.7	11
173	Serum fucose as a monitor for recurrent malignancy. Journal of Surgical Oncology, 1978, 10, 39-44.	1.7	10
174	Tumor Antigens in Ovarian Malignancy. Clinical Obstetrics and Gynecology, 1986, 29, 693-704.	1.1	10
175	Endoluminal ultrasound staging of cervical cancer. Gynecologic Oncology, 1992, 46, 186-190.	1.4	10
176	Tissue-based immune monitoring I. Cancer Biology and Therapy, 2011, 12, 357-366.	3.4	10
177	Cancer-Related Concerns Among Women With a New Diagnosis of Gynecological Cancer: An Exploration of Age Group Differences. International Journal of Gynecological Cancer, 2014, 24, 165-171.	2.5	10
178	Correlation of Pelvic Magnetic Resonance Imaging Diagnosis With Pathology for Indeterminate Adnexal Masses. International Journal of Gynecological Cancer, 2014, 24, 1215-1221.	2.5	10
179	Postoperative complications of epidural analgesia at hysterectomy for gynecologic malignancies: an analysis of the National Surgical Quality Improvement Program. International Journal of Gynecological Cancer, 2020, 30, 1203-1209.	2.5	9
180	Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery. Gynecologic Oncology, 1993, 48, 185-188.	1.4	8

#	ARTICLE	IF	CITATIONS
181	Delayed Hemorrhage After Cervical Conization Unmasking Severe Factor XI Deficiency. <i>Obstetrics and Gynecology</i> , 2004, 104, 1189-1192.	2.4	8
182	Risk of Colorectal Cancer in Women With a Prior Diagnosis of Gynecologic Malignancy. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 291-296.	2.2	8
183	Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma. <i>Journal of Gynecologic Oncology</i> , 2012, 23, 257.	2.2	8
184	Basic Principles of Chemotherapy. , 2018, , 449-469.e2.		8
185	Late effects of cisplatin-based chemotherapy on renal function in patients with ovarian carcinoma. <i>Gynecologic Oncology</i> , 1991, 41, 217-219.	1.4	7
186	Characterization of a human endometrial carcinoma cell line producing intraperitoneal tumor growth in immunodeficient mice. <i>Gynecologic Oncology</i> , 1992, 45, 273-278.	1.4	7
187	Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992, 118, 235-237.	2.5	7
188	Phase II trial of zeniplatin (CL 286 558), a new platinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 1993, 119, 234-236.	2.5	7
189	Salvage Intraperitoneal Mitoxantrone Therapy of Ovarian Cancer: Influence of Increasing the Volume of Treatment. <i>Gynecologic Oncology</i> , 1993, 49, 185-189.	1.4	7
190	Synergistic activity of tumor necrosis factor and interferon in a nude mouse model of human ovarian cancer. <i>Gynecologic Oncology</i> , 1989, 34, 353-356.	1.4	6
191	Early ovarian cancer. <i>Current Treatment Options in Oncology</i> , 2000, 1, 129-137.	3.0	6
192	Cervical Cancer: Successes and Failures. <i>Ca-A Cancer Journal for Clinicians</i> , 2001, 51, 89-91.	329.8	6
193	National Cancer Database Report of Lymphadenectomy Trends in Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1408-1415.	2.5	6
194	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 159, 79-87.	1.4	6
195	Modern treatment options in epithelial ovarian carcinoma. <i>Current Opinion in Obstetrics and Gynecology</i> , 1998, 10, 29-32.	2.0	6
196	Secondary Cytoreductionâ€”Thoughts on the "Pro" Side. <i>Gynecologic Oncology</i> , 1993, 51, 127-130.	1.4	5
197	Cycles of Dose-Intensive Chemotherapy with Peripheral Stem Cell Support in Persistent or Recurrent Platinum-Sensitive Ovarian Cancer. <i>Gynecologic Oncology</i> , 1997, 67, 272-276.	1.4	5
198	Emotion episodes during psychotherapy sessions among women newly diagnosed with gynecological cancers. <i>Psycho-Oncology</i> , 2015, 24, 1189-1196.	2.3	5

#	ARTICLE	IF	CITATIONS
199	Advances in surgery for gynecologic malignancies. <i>Current Opinion in Oncology</i> , 1995, 7, 473-477.	2.4	4
200	Survival of BRCA1 Negative Ovarian Cancer Patients Based on Family History. <i>Gynecologic Oncology</i> , 2001, 83, 109-114.	1.4	4
201	Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 598-604.	1.3	4
202	Endometrial Curettage at the Time of Cervical Conization. <i>Obstetrics and Gynecology</i> , 1986, 67, 663-664.	2.4	3
203	Surgery for gynecologic malignancies. <i>Current Opinion in Oncology</i> , 1992, 4, 923-929.	2.4	3
204	Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992, 118, 391-394.	2.5	3
205	Paget Cells in Endometrial and Endocervical Curettings in a Patient With Recurrent Vulvar Paget's Disease. <i>International Journal of Surgical Pathology</i> , 2014, 22, 374-377.	0.8	3
206	Prophylactic Oophorectomy Comes of Age. <i>Gynecologic Oncology</i> , 2002, 85, 395-396.	1.4	2
207	Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2018, 38, 395-401.	0.9	2
208	Management of Intestinal Obstruction in the Terminal Patient and Management of Ascites. , 2004, , 727-741.		2
209	CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5522-5522.	1.6	2
210	Mitomycin-C Plus a 3-Day Continuous Intravenous Infusion of 5-Fluorouracil: An Inactive Salvage Regimen for Platinum-Resistant Ovarian Carcinoma. <i>Gynecologic Oncology</i> , 1993, 50, 30-33.	1.4	1
211	Initial Surgical Management of Advanced Epithelial Ovarian Cancer. <i>Cancer Investigation</i> , 1997, 15, 270-276.	1.3	1
212	Long-term complications of chemotherapy. <i>Primary Care Update for Ob/Gyns</i> , 1998, 5, 65-68.	0.1	1
213	Maintenance of certification in obstetrics and gynecology: The time has come. <i>Gynecologic Oncology</i> , 2008, 111, 389-390.	1.4	1
214	Advances in cytoreductive surgery of gynecologic cancers. <i>Cancer Treatment and Research</i> , 1998, 95, 203-217.	0.5	1
215	Phase II Trial of Debulking Surgery and Photodynamic Therapy for Disseminated Intraperitoneal Tumors. <i>Annals of Surgical Oncology</i> , 2001, 8, 65-71.	1.5	1
216	Paraortic nodal metastases in early cervical carcinoma: Long-term survival following extended field radiotherapy. <i>Gynecologic Oncology</i> , 1983, 15, 139.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Ovarian Cancer. AORN Journal, 1988, 47, 1427-1437.	0.3	0
218	Palliative Surgery for Intestinal Obstruction in Advanced Ovarian Cancer. Obstetrical and Gynecological Survey, 1990, 45, 73-74.	0.4	0
219	Paget's Disease of the Vulva. Obstetrical and Gynecological Survey, 1991, 46, 387.	0.4	0
220	2197 The role of extended field radiation therapy in early stage cervical carcinoma with para-aortic metastases— A study of survival impact and complication rates. International Journal of Radiation Oncology Biology Physics, 1997, 39, 339.	0.8	0
221	An asymmetric, posterior spacing system for use with mini-ovoids in the treatment of carcinoma of the cervix. International Journal of Gynecological Cancer, 1997, 7, 350-354.	2.5	0
222	Reply. Gynecologic Oncology, 2000, 78, 395.	1.4	0
223	Risk of colorectal cancer in women with a prior diagnosis of gynecological malignancy. Gastroenterology, 2003, 124, A419.	1.3	0
224	Women with a prior diagnosis of breast cancer are not at an increased risk for subsequent colorectal cancer. Gastroenterology, 2003, 124, A644-A645.	1.3	0
225	Basic Principles of Chemotherapy. , 2012, , 515-538.e2.		0
226	Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. Obstetrical and Gynecological Survey, 2016, 71, 344-345.	0.4	0
227	Blood Loss from Robotic Assisted Hysterectomy. Journal of Gynecologic Surgery, 2017, 33, 47-50.	0.1	0
228	Randomized Clinical Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Obstetrical and Gynecological Survey, 2019, 74, 474-476.	0.4	0
229	BRCA1 and BRCA2 Mutations in Ovarian Carcinoma. , 2003, , 201-208.		0
230	Epidemiology, staging and clinical characteristics. , 2005, , 1-37.		0
231	Therapy and Prognosis of BRCA-Associated Ovarian Cancer. , 2008, , 117-127.		0
232	Epidemiology, staging and clinical characteristics. , 2010, , 1-23.		0
233	Quality of care for the initial management of stage IB1-IIA2 invasive cervical carcinomas.. Journal of Clinical Oncology, 2015, 33, e16596-e16596.	1.6	0
234	AWARE: Randomized study of an EMR-based intervention targeting hereditary cancer (CA) risk awareness in peri-op CA patients (pts).. Journal of Clinical Oncology, 2017, 35, e13119-e13119.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritoneal cancer in first relapse (NCT01281514).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5580-5580.	1.6	0
236	Hereditary Issues In Ovarian Cancer. , 2007, , 169-193.		0